se gb

NEWS

Karolinska Development - Interim Report (January-September 2017) - Invitation to conference call and webcast

STOCKHOLM - October 27, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) will publish its Interim Report - January-September 2017 on October 31, 2017. The company will also host a conference call and an online presentation on October 31, at 2 pm CET.

The Company will host a conference call on August 30, 2017 at 2 pm CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call:

From Sweden: +46 (0) 8 505 564 74
From the US: +1 855 753 22 30
From the UK: +44 (0) 20 336 453 74

The presentation will also be webcast and can be accessed from the following web address:
https://edge.media-server.com/m6/p/95yxnc6z

Host: Viktor Drvota, CEO.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network..

For more information, please visit www.karolinskadevelopment.com

PDF    KD Q3 2017 Webcast invitation PR (ENG)